KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Total Current Liabilities (2016 - 2025)

Pacira BioSciences has reported Total Current Liabilities over the past 16 years, most recently at $120.6 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $120.6 million for Q4 2025, down 61.09% from a year ago — trailing twelve months through Dec 2025 was $120.6 million (down 61.09% YoY), and the annual figure for FY2025 was $120.6 million, down 61.09%.
  • Total Current Liabilities for Q4 2025 was $120.6 million at Pacira BioSciences, up from $107.1 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for PCRX hit a ceiling of $521.1 million in Q4 2021 and a floor of $92.7 million in Q2 2024.
  • Median Total Current Liabilities over the past 5 years was $140.5 million (2022), compared with a mean of $199.1 million.
  • Biggest five-year swings in Total Current Liabilities: plummeted 71.64% in 2022 and later skyrocketed 237.86% in 2025.
  • Pacira BioSciences' Total Current Liabilities stood at $521.1 million in 2021, then plummeted by 71.64% to $147.8 million in 2022, then tumbled by 34.1% to $97.4 million in 2023, then soared by 218.25% to $309.9 million in 2024, then tumbled by 61.09% to $120.6 million in 2025.
  • The last three reported values for Total Current Liabilities were $120.6 million (Q4 2025), $107.1 million (Q3 2025), and $313.2 million (Q2 2025) per Business Quant data.